Fascin expression is inversely correlated with breast cancer metastasis suppressor 1 and predicts a worse survival outcome in node-negative breast cancer patients

被引:17
|
作者
Lee, Hye Jin [1 ]
An, Hee Jung [1 ]
Kim, Tae Hoen [1 ]
Kim, Gwangil [1 ]
Kang, Haeyoun [1 ]
Heo, Jin Hyung [1 ]
Kwon, Ah-Young [1 ]
Kim, Sewha [1 ]
机构
[1] CHA Univ, CHA Bundang Med Ctr, Dept Pathol, 59 Yatap Ro, Seongnam Si 13496, Gyeonggi Do, South Korea
来源
JOURNAL OF CANCER | 2017年 / 8卷 / 16期
关键词
breast cancer; fascin; breast cancer metastasis suppressor 1; immunohistochemistry; AGGRESSIVE CLINICAL-COURSE; CARCINOMA METASTASIS; ACTIN CYTOSKELETON; OVARIAN-CARCINOMA; BRMS1; PROTEIN; CELLS; MIGRATION; MOTILITY; MARKER;
D O I
10.7150/jca.22046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Fascin is an actin-bundling protein that promotes cancer cell migration and invasion. By contrast, breast cancer metastasis suppressor 1 (BRMS1) inhibits cancer metastasis by targeting multiple steps of the metastatic cascade. We evaluated whether expression patterns of fascin and BRMS1 correlate with clinicopathological features and patient outcome. Methods: Immunohistochemistry for fascin and BRMS1 was performed using a tissue microarray constructed from 183 human breast cancer tissues. Fascin expression determined by the proportion of stained tumor cells (0: 0-5%, 1: 6-25%, 2: 26-50%, 3: 51-75%, or 4: >75%) and staining intensity (0: negative, 1: weak, 2: moderate, or 3: strong) were multiplied and defined as negative (0-3) or positive (4-12). BRMS1 expression was scored separately based on nuclear and cytoplasmic staining intensity (0: negative, 1: weak, 2: moderate, 3: strong). We obtained the BRMS1 H score by summing the nuclear and cytoplasmic scores and defined it as negative (0-2) or positive (3-6). Results: Expression of BRMS1 showed a significant inverse correlation with that of fascin. Fascin(+) tumors were significantly associated with no lymph node metastasis, higher histological and higher nuclear grade, ER/PR/HER2 negativity, and triple-negative subtype (all ps < 0.05). These clinicopathological differences showed the same trend in a comparison of fascin(-)/BRMS1(+) and fascin(+)/BRMS1(-) tumors. Negative or weak BRMS1 cytoplasmic expression was significantly associated with shorter disease-free survival (DFS; p = 0.043). Fascin positivity was significantly associated with shorter DFS (p = 0.005) and overall survival (p = 0.020) when analyses were confined to node-negative patients. Conclusions: This study confirms an inverse correlation between expression of fascin and expression of BRMS1 using a quite large cohort of human breast cancer tissues. Fascin alone or combined with BRMS1 was a worse prognostic marker, particularly in node-negative breast cancer patients.
引用
收藏
页码:3122 / 3129
页数:8
相关论文
共 50 条
  • [31] Taxanes in the adjuvant treatment of node-negative breast cancer patients
    Ozdemir, N.
    Aksoy, S.
    Zengin, N.
    Altundag, K.
    JOURNAL OF BUON, 2012, 17 (01): : 27 - 32
  • [32] Outcomes in patients with small node-negative invasive breast cancer
    Bao, Jean
    Donovan, Cory
    Amersi, Farin
    Zhang, Xiao
    Giuliano, Armando E.
    Chung, Alice
    BREAST JOURNAL, 2019, 25 (04): : 638 - 643
  • [33] Characteristics and clinical outcome of pT1a-b node-negative breast cancer
    Oyman, Abdilkerim
    Basak, Mustafa
    Odabas, Hatice
    Ozcelik, Melike
    NORTHERN CLINICS OF ISTANBUL, 2021, 8 (02) : 124 - 129
  • [34] Plasma nucleosome levels in node-negative breast cancer patients
    Kuroi K.
    Tanaka C.
    Toi M.
    Breast Cancer, 1999, 6 (4) : 361 - 364
  • [35] PROGNOSTIC ASSESSMENT IN NODE-NEGATIVE BREAST-CANCER PATIENTS
    HOLLAND, R
    VERBEEK, ALM
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) : 1451 - 1453
  • [36] Node-negative breast cancer: Which patients should be treated?
    Schmidt, Marcus
    BREAST CARE, 2008, 3 (04) : 237 - 243
  • [37] Outcomes in Patients With Small Node-Negative Invasive Breast Cancer
    Bao, Jean
    Donovan, Cory
    Amersi, Farin
    Zhang, Xiao
    Giuliano, Armando
    Chung, Alice
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : 35 - 36
  • [38] Perioperative chemotherapy in patients with node-negative postmenopausal breast cancer
    van der Hage, JA
    van de Velde, CJH
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) : 2210 - 2211
  • [39] PROGNOSTIC FACTORS IN PATIENTS WITH NODE-NEGATIVE BREAST-CANCER
    BROCKMANN, B
    WILDNER, GP
    ONKOLOGIE, 1993, 16 (01): : 5 - 10
  • [40] PROGNOSIS IN NODE-NEGATIVE BREAST-CANCER
    VANDEVELDE, CJH
    GALLAGER, HS
    GIACCO, GG
    BREAST CANCER RESEARCH AND TREATMENT, 1986, 8 (03) : 189 - 196